

# Leukocyte Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/L49D9F940EF9EN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: L49D9F940EF9EN

## Abstracts

The 7 major leukocyte disorders markets reached a value of US\$ 57.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 89.6 Billion by 2034, exhibiting a growth rate (CAGR) of 4.18% during 2024-2034.

The leukocyte disorders market has been comprehensively analyzed in IMARC's new report titled "Leukocyte Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Leukocyte disorders, also known as leukocytosis and leukopenia, encompass a range of conditions characterized by abnormal levels of white blood cells (leukocytes) in the bloodstream. Leukocytes play an important role in the immune system, defending the body against infections and diseases. Leukocytosis refers to an increased white blood cell count, often indicative of an underlying infection, inflammatory response, or bone marrow disorder. Symptoms may include fever, fatigue, enlarged lymph nodes, and potential complications related to the underlying cause. Leukopenia, on the other hand, signifies a lower-than-normal white blood cell count, potentially weakening the immune system and leaving the body susceptible to infections. Symptoms of leukopenia can include recurrent infections, slow wound healing, and general malaise. The diagnosis of leukocyte disorders involves a comprehensive assessment of the patient's clinical history, physical examination, and blood workups, such as a complete blood count (CBC), to quantify the different types of white blood cells.

The increasing prevalence of bone marrow dysfunction, which can disrupt the normal production and function of white blood cells, is primarily driving the leukocyte disorders market. In addition to this, the inflating utilization of advanced therapeutic approaches, including targeted therapies and immunomodulatory drugs, is also creating a positive

outlook for the market. These treatments help to restore the balance of white blood cell counts, ensuring a more effective immune response and ultimately ameliorating the symptoms associated with various leukocyte disorders. Moreover, the widespread adoption of supportive care strategies, such as prophylactic antibiotics and growth factors, to enhance the quality of life for patients is further bolstering the market growth. Apart from this, the rising usage of innovative diagnostic methods, including flow cytometry and molecular genetic tests, that facilitate early and accurate diagnosis of the disease is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene-editing technologies like CRISPR, since they can directly modify or correct the genes responsible for the underlying conditions, is also augmenting the market growth. Furthermore, the escalating application of bone marrow and stem cell transplantation techniques aimed at replenishing malfunctioning white blood cells with healthy ones is expected to drive the leukocyte disorders market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the leukocyte disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for leukocyte disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the leukocyte disorders market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the leukocyte disorders market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the leukocyte disorders market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current leukocyte disorders marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

## Market Insights

How has the leukocyte disorders market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the leukocyte disorders market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the leukocyte disorders market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of leukocyte disorders across the seven major markets?

What is the number of prevalent cases (2018-2034) of leukocyte disorders by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of leukocyte disorders by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of leukocyte disorders by type across the seven major markets?

How many patients are diagnosed (2018-2034) with leukocyte disorders across the seven major markets?

What is the size of the leukocyte disorders patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of leukocyte disorders?

What will be the growth rate of patients across the seven major markets?

## Leukocyte Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for leukocyte disorders drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the leukocyte disorders market?

What are the key regulatory events related to the leukocyte disorders market?

What is the structure of clinical trial landscape by status related to the leukocyte disorders market?

What is the structure of clinical trial landscape by phase related to the leukocyte disorders market?

What is the structure of clinical trial landscape by route of administration related to the leukocyte disorders market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 LEUKOCYTE DISORDERS - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 LEUKOCYTE DISORDERS - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 LEUKOCYTE DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Epidemiology by Type (2018-2034)
  - 7.2.6 Diagnosed Cases (2018-2034)
  - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Epidemiology by Type (2018-2034)
  - 7.3.6 Diagnosed Cases (2018-2034)
  - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Epidemiology by Type (2018-2034)
  - 7.4.6 Diagnosed Cases (2018-2034)
  - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Epidemiology by Type (2018-2034)
  - 7.5.6 Diagnosed Cases (2018-2034)
  - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Epidemiology by Type (2018-2034)
  - 7.6.6 Diagnosed Cases (2018-2034)

- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)
  - 7.7.4 Epidemiology by Gender (2018-2034)
  - 7.7.5 Epidemiology by Type (2018-2034)
  - 7.7.6 Diagnosed Cases (2018-2034)
  - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Epidemiology by Type (2018-2034)
  - 7.8.6 Diagnosed Cases (2018-2034)
  - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Epidemiology by Type (2018-2034)
  - 7.9.6 Diagnosed Cases (2018-2034)
  - 7.9.7 Patient Pool/Treated Cases (2018-2034)

## **8 LEUKOCYTE DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 LEUKOCYTE DISORDERS - UNMET NEEDS**

## **10 LEUKOCYTE DISORDERS - KEY ENDPOINTS OF TREATMENT**

## **11 LEUKOCYTE DISORDERS - MARKETED PRODUCTS**

- 11.1 List of Leukocyte Disorders Marketed Drugs Across the Top 7 Markets



### 11.1.1 Neupogen (Filgrastim) - Amgen/Roche

#### 11.1.1.1 Drug Overview

#### 11.1.1.2 Mechanism of Action

#### 11.1.1.3 Regulatory Status

#### 11.1.1.4 Clinical Trial Results

#### 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 LEUKOCYTE DISORDERS - PIPELINE DRUGS**

### 12.1 List of Leukocyte Disorders Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Mavorixafor - X4 Pharmaceuticals

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. LEUKOCYTE DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. LEUKOCYTE DISORDERS – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 LEUKOCYTE DISORDERS - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Leukocyte Disorders - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Leukocyte Disorders - Market Size by Therapies

- 15.2.2.1 Market Size by Therapies (2018-2023)
- 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Leukocyte Disorders - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Leukocyte Disorders - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Leukocyte Disorders - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Leukocyte Disorders - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Leukocyte Disorders - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Leukocyte Disorders - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Leukocyte Disorders - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Leukocyte Disorders - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Leukocyte Disorders - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Leukocyte Disorders - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Leukocyte Disorders - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Leukocyte Disorders - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Leukocyte Disorders - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Leukocyte Disorders - Market Size by Therapies

- 15.7.2.1 Market Size by Therapies (2018-2023)
- 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Leukocyte Disorders - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Leukocyte Disorders - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Leukocyte Disorders - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Leukocyte Disorders - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Leukocyte Disorders - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Leukocyte Disorders - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Leukocyte Disorders - Access and Reimbursement Overview

## **16 LEUKOCYTE DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 LEUKOCYTE DISORDERS MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 LEUKOCYTE DISORDERS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Leukocyte Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/L49D9F940EF9EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L49D9F940EF9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

